These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21081599)

  • 21. [Orphan drugs: towards an economic evaluation].
    Holué C
    Rev Prat; 2012 Jan; 62(1):91-4. PubMed ID: 22335077
    [No Abstract]   [Full Text] [Related]  

  • 22. Policy alternatives for treatments for rare diseases.
    Panju AH; Bell CM
    CMAJ; 2010 Nov; 182(17):E787-92. PubMed ID: 20624867
    [No Abstract]   [Full Text] [Related]  

  • 23. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 24. The balancing act of orphan drug pricing.
    The Lancet
    Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
    [No Abstract]   [Full Text] [Related]  

  • 25. [Orphan drugs and drug pirates].
    Bannenberg WJ; 't Hoen EFM
    Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceuticals. Adopt an orphan.
    Karr A
    Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
    [No Abstract]   [Full Text] [Related]  

  • 27. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 29. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 31. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 32. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Companies look for profit in orphan drugs.
    Thompson CA
    Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drugs for rare diseases: the blessing of being orphans.].
    Costa E; Schieppati A; Luzzatto L; Remuzzi G
    Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Support system: through charities, drug makers help people--and themselves.
    Anand G
    Wall St J (East Ed); 2005 Dec; ():A1, A10. PubMed ID: 16502554
    [No Abstract]   [Full Text] [Related]  

  • 36. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
    Clarke JT
    CMAJ; 2006 Jan; 174(2):189-90. PubMed ID: 16415465
    [No Abstract]   [Full Text] [Related]  

  • 37. The rising cost of orphan drugs.
    Lancet Haematol; 2015 Nov; 2(11):e456. PubMed ID: 26686251
    [No Abstract]   [Full Text] [Related]  

  • 38. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.